RYTM Q4 2022 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+383.8% YoY

Gross Profit

$8M88.3% margin

Operating Income

-$42M-479.0% margin

Net Income

-$42M-483.4% margin

EPS (Diluted)

$-0.75

QoQ Revenue Growth

+105.2%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$34M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$382M

Total Liabilities

$118M

Stockholders' Equity

$264M

Cash & Equivalents

$128M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$2M	+383.8%
Gross Profit	$8M	$2M	+391.0%
Operating Income	-$42M	-$51M	+17.4%
Net Income	-$42M	-$43M	+0.9%

Revenue Segments

Product revenue

$9M100%